Adler M, Deshpande SS, Foster RE, Maxwell DM. Effects of subacute pyridostigmine administration on mammalian skeletal muscle function. J Appl Toxicol. 1992;12:25-33.
Barbarino A, Corsello SM, Tofani A, et al. Sexual dimorphism of pyridostigmine potentiation of growth hormone (GH)-releasing hormone-induced GH release in humans. J Clin Endocrinol Metab. 1991;73:75-78.
Borland RG, Brennan DH, Nicholson AN, Smith PA. Studies on the possible central and peripheral effects in man of cholinesterase inhibitor (pyridostigmine). Human Toxicology. 1985;4:293-300.
Bowman PD, Schuschereba ST, Johnson TW, et al. Myopathic changes in diaphragm of rats fed pyridostigmine bromide subchronically. Fundam Appl Toxicol. 1989;13:110-117.
Breyer-Pfaf U, Maier U, Brinkmann AM, Schumm F. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis. Clin Pharmacol Ther. 1985;37:495-501.
Briggs GC, Freeman RK, Yaffe SJ, eds. Drugs in Pregnancy and Lactation. Baltimore, Md: Williams & Wilkins; 1990:543-544.
Cook JE, Wenger CB, Kolka MA. Chronic pyridostigmine bromide administration: side effects among soldiers working in a desert environment. Mil Med. 1992;157:250-254.
Dettbarn W-D. Anticholinesterase-induced myonecrosis. In: Ballantyne B, Marrs TC, eds. Clinical and Experimental Toxicology of Organophosphates and Carbamates. Oxford: Butterworth; 1992:167-179.
Diruhumber P, French MC, Green DM, Leadbeater L, Stratton JA. The protection of primates against soman poisoning by pretreatment with pyridostigmine. J Pharmacol. 1979;31:295-299.
Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330:1797-1810.
Ellman GL, Courtney DK, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical Pharmacology. 1961;7:88-95.
Fenichel GM, Kibler WB, Dettbarn W-D. The effect of immobilization and exercise on acetylcholine-mediated myopathies. Neurology. 1974;24:1086-1090.
French MC, Wetherell JR, White PDT. The reversal by pyridostigmine of neuromuscular block produced by soman. J Pharmacy and Pharmacology. 1979;31:290-294.
Gall P. The use of therapeutic mixtures in the treatment of cholinesterase inhibition. Fundam Appl Toxicol. 1981;1:214-216.
Gebbers J-O, Lotscher M, Kobel W, Portmann R, Laissue J-A. Acute toxicity of pyridostigmine in rats: histological findings. Arch Toxicol. 1986;58:271-275.
Glikson M, Achiron A, Ram Z, et al. The influence of pyridostigmine administration on neuromuscular functions-studies in healthy human subjects. Fundam Appl Toxicol. 1991;16:288-298.
Gordon JJ, Leadbeater L, Maidment MP. The protection of animals against organophosphate poisoning by pretreatment with a carbamate. Toxicol Appl Pharmacol. 1978;43:207-216.
Graham C. Oral Dose Effects of Pyridostigmine on Human Performance. 4th Annual Chemical Defense Bioscience Review; Fort Detrick, Md; 1984. Proceedings.
Gupta RC, Patterson GT, Dettbarn W-D. Mechanisms of toxicity and tolerance to diisopropylphosphofluoridate at the neuromuscular junction of the rat. Tosicol Appl Pharmacol. 1986;84:541-550.
Harris L, Stitcher D. Protection against diisopropylfluorophosphate intoxication by pyridostigmine and physostigmine in combination with atropine and mecamylamine. Arch Pharmacol. 1984;327:64-69.
Harris LW, Talbot BG, Anderson DR, Lennox WJ, Green MD. Oxime-induced decarbamylation and atropine/oxime therapy of guinea pigs intoxicated with pyridostigmine. Life Sci. 1987;40:577-583.
Harris LW, Talbot BG, Lennox WJ, Anderson DR. The relationship between oxime-induced reactivation of carbamylated acetylcholinesterase and antidotal efficacy against carbamate intoxication. Toxicol Appl Pharmacol. 1989;98:128-133.
Hubert M, Lison D. Study of muscular effects of short-term pyridostigmine treatment in resting and exercising rats. Hum Exp Toxicol. 1995;14:49-54.
Husdon CS, Foster RE, Kahng MW. Neuromuscular toxicity of pyridostigmine bromide in the diaphragm, extensor digitorum longus, and soleus muscles of the rat. Fundam Appl Toxicol. 1985;5(suppl):S260-S269.
Inns RH, Marrs T. Prophylaxis against anticholinesterase poisoning. In: Ballantyne B, Marrs TC, eds. Clinical and Experimental Toxicology of Organophosphates and Carbamates. Oxford: Butterworth; 1992:602-610.
Israeli S, Avgar D, Almog S, et al. The effect of repeated doses of 30 mg pyridostigmine bromide on pilot performance in an A-4 flight simulator. Aviat Space Environ Med. 1990;61:430-432.
Keeler JR, Hurst CG, Dunn MA. Pyridostigmine used as a nerve agent pretreatment under wartime conditions. JAMA. 1991;266:693-695.
Kolka MA, Burgoon PW, Quigley MD, et al. Red Blood Cell Cholinesterase Activity and Plasma Pyridostigmine Concentration During Single and Multiple Dose Studies. US Army Research Institute of Environmental Medicine; 1991. Technical Report #T3-91.
Koplovitz I, Harris LW, Anderson DR, Lennox WJ, Stewart JR. Reduction of pyridostigmine pretreatment of the efficacy of atropine and 2-PAM treatment of sarin and VX poisoning in rodents. Fundam Appl Toxicology. 1992;18:102-106.
Kornhauser D, Petty B, Lietman P. Bioavailability of Oral Pyridostigmine and Inhibition of Red Blood Cell Acetylcholinesterase by Oral and Intravenous Pyridostigmine. Baltimore, Md: The Johns Hopkins University School of Medicine; 1986. Contract DAMD17-85-C-5133; AD A181670.
Lennox WJ, Harris LW, Talbot BG, Anderson DR. Relationship between reversible acetylcholinesterase inhibition and efficacy against soman lethality. Lif Sci. 1985;37:793-798.
Loewenstein-Lichtenstein Y, Schwarz M, Glick D, Norgaard-Pedersen B, Zakut H, Soreq H. Genetic predisposition to adverse consequences of anti-cholinesterase in "atypical" BCHE carriers. Nature Medicine. 1995;1:1082-1085.
Lotti M, Moretto A. Cholinergic symptoms and Gulf War syndrome. Nature Medicine. 1995;1(12): 1225-1226. Letter.
McNall PG, Wolfson B, Tuazon JG, Siker ES. Use of pyridostigmine for the reversal of neuromuscular junction blockade. Anesth Analg. 1969;48:1026-1032.
Neish SR, Carter B. More on Desert Storm . JAMA.1991;266(23):3282-3283. Letter.
O'Keane V, Dinan TG. Sex steroid priming effects on growth hormone response to pyridostigmine throughout the menstrual cycle. J Clin Endocrinol Metab. 1992;75:11-14.
Ram Z, Molcho M, Danon YL, et al. The effect of pyridostigmine on respiratory function in healthy and asthmatic volunteers. Isr J Med Sci. 1991;27(11-12):664-668.
Sarno AP. More on Desert Storm. JAMA. 1991;266(23):3282. Letter.
Scadding GK, Havard CWH, Lange MJ, Domb I. The long-term experience of thymectomy for myasthenia gravis. J Neurol Neurosurg Psychiatry. 1985;48:401-406.
Sharabi Y, Danon YL, Berkenstadt H, et al. Survey of symptoms following intake of pyridostigmine during the Persian Gulf War. Isr J Med Sci. 1991;27:656-658.
Solana RP, Gennings C, Carter WH, et al. Evaluation of the efficacy of two carbamates, physostigmine and pyridostigmine, when used in conjunction for protection against organophosphate exposure. Fundam Appl Toxicol. 1990;15:814-819.
Thompson T, Kewitz H, Pluel O. Estimation of cholinesterase activity in undiluted plasma and erythrocyte as a tool for measuring in vivo effect of reversible inhibitors. J Clin Chem Biochem. 1988;26:469-475.
Vanneste Y, Lison D. Biochemical changes associated with muscle fibre necrosis after experimental organophosphate poisoning. Hum Exp Toxicol. 1993;12:365-370.
Wacks I, Oster JR, Perez GO, Kett DH. Spurious hyperchloremia and hyperbiocarbonatemia in a patient receiving pyridostigmine bromide therapy for myasthenia gravis. Am J Kidney Dis. 1990;16:76-79.
Wenger CB, Latzka WA. Effects of pyridostigmine bromide on physiological responses to heat, exercise and hypohydration. Aviat Space Environ Med. 1992;63:37-45.